The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis ...
Mounjaro(tirzepatide) is aonce-weekly injectionthat’s closely related to GLP-1 receptor agonist drugs. It’s part of a brand new class called GLP-1/GIP agonists. Itworks bymimicking two gut hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is approved to tre...
The present invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prop...
Brand CL, Galsgaard ED, Tornehave D, Romer J, Gotfredsen CF, Wassermann K, Knudsen LB, Volund A and Sturis J: Synergistic effect of the human GLP‑1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats. Diabetes...
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipi...